Welcome to LookChem.com Sign In|Join Free
  • or

7491-74-9

Post Buying Request

7491-74-9 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Piracetam powder 7491-74-9
Cas No: 7491-74-9
USD $ 20.0-25.0 / Kilogram 1 Kilogram 2000 Kilogram/Day ShangHai Soyoung Biotechnology Inc Contact Supplier
Piracetam
Cas No: 7491-74-9
USD $ 20.0-20.0 / Kilogram 1 Kilogram 1 Metric Ton/Day DB BIOTECH CO., LTD Contact Supplier
Piracetam CAS NO.7491-74-9
Cas No: 7491-74-9
No Data 1 Kilogram 500 Metric Ton/Month Shanghai PengMo Biotechnology Co.,Ltd Contact Supplier
Raw Material Piracetam Powder
Cas No: 7491-74-9
USD $ 395.0-400.0 / Kilogram 10 Kilogram 100 Kilogram/Day Arshine Pharmaceutical Co., Limited Contact Supplier
99.9% Pure Piracetam powder, no customs issues
Cas No: 7491-74-9
USD $ 58.0-68.0 / Kilogram 2 Kilogram 5000 Kilogram/Month Guangzhou Tengyue Chemical Co., Ltd. Contact Supplier
Piracetam
Cas No: 7491-74-9
No Data No Data No Data shanghai Longyu biotechnology Co.,Ltd Contact Supplier
Piracetam
Cas No: 7491-74-9
No Data No Data No Data Hangzhou Yierdechem Co. Ltd Contact Supplier
Piracetam Manufacturer/High quality/Best price/In stock
Cas No: 7491-74-9
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier
High purity Various Specifications Piracetam CAS:7491-74-9
Cas No: 7491-74-9
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
High quality Piracetam(Naofukang) supplier in China
Cas No: 7491-74-9
No Data No Data Metric Ton/Day Simagchem Corporation Contact Supplier

7491-74-9 Usage

Side effects

Despite that piracetam is regarded as a relatively safe nootropic, some users may still experience side effects and adverse reactions[30]. The severity and number of side effects experienced from piracetam is subject to significant individual variation. One user may not perceive any side effects, while another may notice severe adverse reactions. Of all those reported piracetam side effects, the most common include: nervousness, increased body movements(hyperkinesia), and weight gain. Some rare cases may also include agitation, anxiety, brain fog, cognitive impairment, depression, fatigue, hemocrit/hemoglobin levels change, headaches, hyperkinesia, insomnia, irritability, libido increase, lightheadedness, muscle spasms, nausea, restlessness, shakiness, sleep disturbances, speech impairment, somnolence, sweating, visual change and weakness.

Pharmacological effects

Neuronal effects
Piracetam has important effects on neurotransmission that are not limited to any one type of neurotransmitter. It has been shown to influence cholinergic[3,4], serotoninergic[5], noradrenergic[6], and glutamatergic[7] systems. The modulation of these systems by piracetam does not result from direct receptor agonism or antagonism(piracetam has no affinity for these receptors; Ki > 10 μM)[8]. Instead, piracetam appears to in- crease the number of postsynaptic receptors and or restore the function of these receptors. The effect of piracetam on cholinergic and glutamatergic systems is likely to be particularly relevant to its clinical benefit in cognitive disorders, given the increasing evidence that dysfunction in these systems may be related to cognitive decline[9,10]. Preclinical studies have shown that piracetam appears to offer neuroprotective benefits. This is consistent with the suggestion that interactions between piracetam and membrane lipids may decrease the risk of membrane fusion[11]. Piracetam has been shown to reduce the incidence of animal death following barbiturate overdose, and to protect against morphological changes related to long-term alcohol use[12]. The anticonvulsant action of piracetam has also been documented in animal studies. Administration of piracetam prior to a convulsant stimulus reduces seizure severity in rats prone to audiogenic attacks[13].
Vascular effects
Studies suggest that piracetam exerts a number of effects on erythrocytes, such as decreased adhesion to endothelium[14]. These effects are likely to facilitate movement of erythrocytes through the circulation. Studies have also indicated that piracetam exerts an effect on blood vessels. For example, in vitro, 2 mg/kg piracetam decreased the time taken for rabbit pial vessels to return to normal diameter following a period of induced arteriolar spasm(10.4 vs. 5.1 min for 0.02 and 2 mg/kg of piracetam, respectively)[15]. Piracetam may also influence blood coagulation. In healthy humans, a single dose of piracetam(3.2 to 9.6 g) reduced plasma levels of fibrinogen and von Willebrand factor in a dose-dependent manner by up to 40%[16]. Enhanced cerebral blood flow has been reported following piracetam treatment in hypotensive cats and in humans with acute cerebral ischemia[17,18]. Additionally, piracetam appears to influence microcirculation at the peripheral level. Following treatment with piracetam, renal blood flow was significantly greater in ischemically damaged rat kidneys relative to controls[19], and, in a separate experiment, blood flow significantly increased in the cochlea of guinea pigs without any marked change in blood pressure[20].

Uses

antinauseant

References

  1. Giurgea C. Vers une pharmacologie de l’activite? inte?grative du cerveau. Tentative du concept nootrope en psychopharmacologie. [Towards an integrative pharmacology of the activity of the brain. Attempt at the nootropic concept in psychopharmacology]. Actual Pharmacol[Paris] 1972;25:115–176.
  2. Winnicka, K., Tomasiak, M., & Bielawska, A.[2005]. Piracetam--an old drug with novel properties? Acta Poloniae Pharmaceutica, 62(5], 405.
  3. Mu?ller WE. Age related quantitative and qualitative receptor changes and pharmacological reactivity. In: Racagni G, Mendlewicz J, Eds. Treatment of age-related cognitive dysfunction: Pharmacological and clinical evaluation. Int Acad Biomed Drug Res. Basel: Karger 1992;2:35–40.
  4. Pilch H, Mu?ller WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology 1988;94:74–78.
  5. Valzelli L, Bernasconi S, Sala A. Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatry 1980;15:150–156.
  6. Olpe H-R, Steinmann MW. The activating action of vincamine, piracetam and hydergine on the activity of the noradrenergic neurons of the locus coeruleus. Behav Neural Biol 1981;33:249–251.
  7. Cohen SA, Mu?ller WE. Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology 1993;47:217–222
  8. Gualtieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics, contro- versial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 2002;8:125–138.
  9. Segovia G, Porras A, Del Arco A, Mora F. Glutamatergic neurotransmission in aging: A critical perspective. Mech Ageing Dev 2001;122:1–29.
  10. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306:821–827.
  11. Mingeot-Leclercq M-P, Lins L, Bensliman M, et al. Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Aa? C-terminal fragment. Biochim Biophys Acta 2003;1609:28–38.
  12. Brandao F, Paula-Barbosa MM, Cadete-Leite A. Piracetam impedes hippocampal neuronal loss during with- drawal after chronic alcohol intake. Alcohol 1995;12:279–288.
  13. Benesova O. The effects of nootropic drugs on the susceptibility to audiogenic seizures in rats. Act Nerv Super[Praha] 1980;22:192–193.
  14. Nalbandian RM, Henry RL, Burek CL, et al. Diminished adherence of sickle erythrocytes to cultured vas- cular endothelium by piracetam. Am J Hematol 1983;15:147–151.
  15. Reuse-Blom S. Microcirculation of the pial vessels in the rabbit. Acta Cardiol 1979;34:35–36.
  16. Moriau M, Crasborn L, Lavenne-Pardonge E, Von Frenckell R, Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. Arzneimittelforschung 1993;43:110–118.
  17. Herrschaft H. The effect of piracetam on global and regional cerebral blood flow in acute cerebral ischemia of man. Med Klin 1978;73:195–202.
  18. Sato M, Heiss WD. Effect of piracetam on cerebral blood flow and somatosensory evoked potential during normotension and hypotensive ischemia in cats. Arzneimittelforschung 1985;35:790–792.
  19. Gianello P, Janssen T, Chatzopoulos C, et al. Beneficial effect of piracetam on renal blood flow in ischemi- cally injured kidneys in the rat. Transplant Proc 1988;20:914–916.
  20. Maass B, Soetanto R. Pru?fung der Wirkung von Piracetam auf die Wasserstoff — Clearance am Innenohr [Examination of the effect of piracetam on the hydrogen clearance to the inner ear]. Laryngorhinootologie 1988;67:132–135.
  21. Gobert JG. Gene?se d’un me?dicament: le piracetam. Me?tabolisation et recherche biochimique. [Genesis of the drug piracetam. Metabolism and biochemical research]. J Pharm Belg 1972;27:281–304.
  22. Gobert JG, Baltes EL. Availability and plasma clearance of piracetam in man. Farmaco 1977;3:84–91.
  23. Alberts B, Bray D, Lewis J, et al. Molecular biology of the cell. Chapter 10. 3rd Edition. New York: Garland publishing Inc., 1994.
  24. Crews FT. Effects of membrane fluidity on secretion and receptor stimulation. Psychopharmacol Bull 1982; 18:135–143.
  25. Peuvot J, Schank A, Deleers M, Brasseur R. Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol 1995;50:1129–1134.
  26. Scheuer K, Stoll S, Paschke U, Weigel R, Mu?ller WE. N-methyl-D-aspartate receptor density and membrane fluidity as possible determinants of the decline of passive avoidance performance in aging. Pharmacol Bio- chem Behav 1995;50:65–70.
  27. Mu?ller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997;53:135–140.
  28. Eckert GP, Cairns NJ, Mu?ller WE. Piracetam reverses hippocampal membrane alterations in Alzheimer’s disease. J Neural Transm 1999;106:757–761.
  29. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993;8:63–68.
  30. https://mentalhealthdaily.com/2015/12/18/piracetam-side-effects-adverse-reactions-list/

Contradictions and drug interactions

Due to its renal clearance, piracetam dose should be adjusted in patients with renal in- sufficiency and the drug is contraindicated in patients with end-stage renal disease. Piracetam should not be prescribed to patients with cerebral hemorrhage. While reproductive studies in animals have not identified any risk to the fetus, studies in humans have not been conducted and so the use of piracetam in pregnant or lactating women should be avoided. Piracetam is neither metabolized by the liver nor bound to plasma albumin. The potential for drug–drug interactions is, therefore, low. Although piracetam enhances the anticonvulsant effects of carbamazepine, no interactions with sodium valproate have been reported[29]. There are no known interactions of piracetam with any other drugs.

Chemical Properties

White Solid

Toxicity

Piracetam is remarkably well tolerated. In preclinical trials, no irreversible toxicity was reported in mice, rats or dogs receiving single oral doses of up to 10 g/kg. In a pooled analysis of 91 double-blind, placebo-controlled studies, hyperkinesia, weight gain, nervousness, somnolence, depression and asthenia were slightly increased with piracetam, although the incidence of each of these events was less than 2%.

Indication

It is indicated in the case of adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies.

Uses

Nootropic.

Mode of action

Although piracetam is a derivative of GABA, its mechanism of action appears to be unrelated to the properties of this neurotransmitter. While the exact mode of action of piracetam is a matter of debate, there is increasing evidence that its underlying effect is to restore cell membrane fluidity. Cell membranes comprise a bilayer of lipid molecules interspersed with protein molecules. These membranes are fluid structures in which the molecules comprising the membrane can diffuse while maintaining this overall arrangement. Membrane fluidity is believed to be important for a number of activities including membrane transport, enzyme activity, chemical secretion, and receptor binding and stimulation[23,24]. Piracetam can have direct interaction with the membrane. The resultant mobile drug–lipid complexes are thought to induce the reorganization of lipids, which may influence membrane function and fluidity[25]. Studies have also demonstrated that piracetam influences membrane fluidity, particularly when normal fluidity is compromised, as is often seen during aging[26]. Several in vitro studies have assessed fluidity during piracetam treatment using anisotropy of membrane-bound DPH[1,6-diphenyl-1,3,5-hexatriene]. Incubation with piracetam restored fluidity in brain membranes of elderly mice with diminished fluidity but had no effect on brain membranes of younger mice with normal fluidity[27]. Similarly, in other studies using in vitro anisotropy techniques, fluidity was restored in the membranes of aged rat and aged human brains following incubation with piracetam[27]. Similar effects were observed in hippocampal membranes from patients with Alzheimer’s disease[28]. This improvement of fluidity coincided with significantly improved avoidance learning[27]. No effect of piracetam on learning or membrane fluidity was found in young rats receiving piracetam. Through restored membrane fluidity, piracetam can promote restored neurotransmission such as glutamatergic and cholinergic systems, enhances neuroplasticity and mediates neuroprotective and anticonvulsant effects at the neuronal level. It has also been found that piracetam can also improves the fluidity of platelet membranes and decreases adhesion of erythrocytes to cell wall as well as reduces vasospasm which in turn improves microcirculation including cerebral and renal blood flow[23,24].

Purification Methods

This typical nootropic (Alzheimer) drug modulates Na flux in AMPA receptors and is purified by recrystallisation from isoPrOH. [Gouilaev & Senning Brain Research Rev 19 180 1994.]

Biological Activity

Nootropic that displays cognitive enhancing properties. Proposed to enhance neurotransmission via modulation of ion flux; potentiates Na + influx through AMPA receptors. Facilitates efficiency of cholinergic neurotransmission at muscarinic receptors.

Pharmacokinetics

Piracetam is rapidly absorbed. Following oral administration, peak plasma concentrations in fasting subjects are achieved in approximately 30 min[22]. Following a single oral dose of 3.2 g, peak concentration is typically 84 ug/mL. Oral formulations of piracetam are extensively absorbed with a bioavailability close to 100%[22]. No metabolites of piracetam have yet been discovered and the drug is excreted unchanged in the urine by glomerular filtration[21]. While food does not affect the extent of absorption of piracetam, it does decrease the maximal plasma concentration of the drug by 17% and prolong Tmax to 1.5 h. Piracetam crosses blood–brain and placental barriers and is found in all tissues, except adipose tissue. The uptake into the brain is less rapid than into the circulation, and, at nearly 8 h, half-life in cerebrospinal fluid is longer than in plasma(about 5 h)[21].

Overview

Piracetam is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid(GABA), originally marketed in 1971 by UCB Pharma. It was the first “nootropic” drug[1], an agent that acts on cognitive function without causing sedation or stimulation. While the mechanisms of action of piracetam have yet to be fully elucidated, it influences neuronal and vascular functions. Furthermore, vascular effects are peripheral as well as central, meaning that the clinical benefit of piracetam goes beyond its nootropic features. Indeed, piracetam is now indicated for use in vertigo, dyslexia, cortical myoclonus and sickle cell anemia in addition to age-related cognitive disorders. Piracetam has been available for over 40 years. Its efficacy has been recorded in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia, however, the clinical application in these conditions is not yet established. Piracetam also has effects on the vascular system through reducing erythrocyte adhesion to vascular endothelium, hinder vasospasm and facilitate microcirculation[2].

Figure 1 The chemical structure of piracetam ;
InChI:InChI=1/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)

7491-74-9 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
Sigma (P5295)  Piracetam   7491-74-9 P5295-25G 830.70CNY Detail
Sigma-Aldrich (Y0000288)  Piracetam  European Pharmacopoeia (EP) Reference Standard 7491-74-9 Y0000288 1,880.19CNY Detail

7491-74-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(2-oxopyrrolidin-1-yl)acetamide

1.2 Other means of identification

Product number -
Other names 2-Oxo-1-pyrrolidineacetamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:7491-74-9 SDS

7491-74-9Synthetic route

2-(3,4-dimethoxyphenyl)-ethylamine
120-20-7

2-(3,4-dimethoxyphenyl)-ethylamine

N,N-Dimethyl-N'-(pyrrolidon-2-yl-1-acetyl)formamidine
92884-66-7

N,N-Dimethyl-N'-(pyrrolidon-2-yl-1-acetyl)formamidine

A

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

B

N,N-dimethyl-N'-homoveratrylformamidine
61945-49-1

N,N-dimethyl-N'-homoveratrylformamidine

Conditions
ConditionsYield
In benzene for 4h; Ambient temperature;A 100%
B n/a
In benzene for 4h; Ambient temperature;
nitrile of 2-oxopyrrolidine-1-acetic acid
57275-83-9

nitrile of 2-oxopyrrolidine-1-acetic acid

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
With manganese(IV) oxide; water In isopropyl alcohol at 100℃; under 5171.62 Torr; for 0.25h;97%
With C34H38N6NiO2(2+)*2Cl(1-); water In isopropyl alcohol at 100℃; for 24h; Schlenk technique; Inert atmosphere;65%
With water; C34H38N6NiO2(2+)*2Cl(1-) In isopropyl alcohol at 100℃; for 24h;65%
methyl 2-oxo-1-pyrrolidineacetate
59776-88-4

methyl 2-oxo-1-pyrrolidineacetate

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
With ammonia In methanol at 60℃; for 4h; Sealed tube;93%
With ammonium hydroxide for 2h;78%
With ammonia In methanol at 60℃; for 4h;45.94%
2-(oxo-pyrrolidin-1-yl)-acetic acid ethyl ester
61516-73-2

2-(oxo-pyrrolidin-1-yl)-acetic acid ethyl ester

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
With ammonium hydroxide for 2h;91%
4-[(2-amino-2-oxoethyl)amino]butanoic acid acetate

4-[(2-amino-2-oxoethyl)amino]butanoic acid acetate

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
Heating;75%
1-(2-hydroxyethyl)-2-pyrrolidinone
3445-11-2

1-(2-hydroxyethyl)-2-pyrrolidinone

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
With tert.-butylhydroperoxide; ammonium hydroxide In water at 100℃; for 16h;73%
α-aminoacetamide hydrochloride

α-aminoacetamide hydrochloride

4-Chlorobutanoyl chloride
4635-59-0

4-Chlorobutanoyl chloride

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
Stage #1: α-aminoacetamide hydrochloride In acetonitrile Inert atmosphere;
Stage #2: 4-Chlorobutanoyl chloride With sodium hydroxide In acetonitrile at 0 - 5℃; for 3h; Reagent/catalyst; Solvent; Temperature;
70%
2-(4-chlorobutyramido)acetamide
64026-51-3

2-(4-chlorobutyramido)acetamide

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
With sodium ethanolate In ethanol at 50℃; for 8h;45%
(2,4-dioxopyrrolidin-1-yl)acetamide hydrochloride
142352-10-1

(2,4-dioxopyrrolidin-1-yl)acetamide hydrochloride

A

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

C

4-hydroxy-2-oxo-1-pyrrolidine acetic acid
77191-37-8

4-hydroxy-2-oxo-1-pyrrolidine acetic acid

D

3-(1-(carbamoylmethyl)-2-oxo-3-pyrrolin-4-yl)-4-hydroxy-2-oxo-3-pyrroline-1-acetamide
105240-61-7

3-(1-(carbamoylmethyl)-2-oxo-3-pyrrolin-4-yl)-4-hydroxy-2-oxo-3-pyrroline-1-acetamide

Conditions
ConditionsYield
With hydrogen; Ru-carbon In water under 18751.5 Torr; for 20h; Ambient temperature;A n/a
B 45%
C 24%
D n/a
(1,5-dihydro-4-methoxy-2-oxo-2H-pyrrol-1-yl)acetamide
114012-62-3

(1,5-dihydro-4-methoxy-2-oxo-2H-pyrrol-1-yl)acetamide

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
With hydrogen; platinum on activated charcoal Yield given;
Multi-step reaction with 2 steps
1: 96 percent / HCl / acetic acid / 2 h / 30 °C
2: H2 / 5percent Ru/C / H2O / 20 h / 18751.5 Torr / Ambient temperature
View Scheme
2-(2,4-dioxopyrrolidine-1-yl)acetamide
85614-54-6

2-(2,4-dioxopyrrolidine-1-yl)acetamide

A

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

C

3-(1-(carbamoylmethyl)-2-oxo-3-pyrrolin-4-yl)-4-hydroxy-2-oxo-3-pyrroline-1-acetamide
105240-61-7

3-(1-(carbamoylmethyl)-2-oxo-3-pyrrolin-4-yl)-4-hydroxy-2-oxo-3-pyrroline-1-acetamide

Conditions
ConditionsYield
With methanesulfonic acid; hydrogen; Pt/Al2O3 under 11250.9 Torr; for 14h; Yield given. Yields of byproduct given;
<4-(benzyloxy)-1,5-dihydro-2-oxo-2H-pyrrol-1-yl>acetamide
113896-94-9

<4-(benzyloxy)-1,5-dihydro-2-oxo-2H-pyrrol-1-yl>acetamide

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: H2 / 5percent Pd/C / dimethylamine / 3 h / 3750.3 Torr / Ambient temperature
2: H2, MeSO3H / Pt/Al2O3 / 14 h / 11250.9 Torr
View Scheme
(4-Benzyloxy-2-oxo-2,5-dihydro-pyrrol-1-yl)-acetic acid ethyl ester

(4-Benzyloxy-2-oxo-2,5-dihydro-pyrrol-1-yl)-acetic acid ethyl ester

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: liq. NH3, MsOH / 8 h / 55 °C
2: H2 / 5percent Pd/C / dimethylamine / 3 h / 3750.3 Torr / Ambient temperature
3: H2, MeSO3H / Pt/Al2O3 / 14 h / 11250.9 Torr
View Scheme
ethyl (2,5-dihydro-4-methoxy-2-oxo-1H-pyrrol-1-yl)acetate
110104-61-5

ethyl (2,5-dihydro-4-methoxy-2-oxo-1H-pyrrol-1-yl)acetate

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 95 percent / liq. NH3 / methanol / 6 h / 60 °C
2: H2 / Pt/C
View Scheme
Multi-step reaction with 3 steps
1: 95 percent / liq. NH3 / methanol / 6 h / 60 °C
2: 96 percent / HCl / acetic acid / 2 h / 30 °C
3: H2 / 5percent Ru/C / H2O / 20 h / 18751.5 Torr / Ambient temperature
View Scheme
Multi-step reaction with 4 steps
1: MsOH / 3 h / 90 - 100 °C / 12 - 18.8 Torr
2: liq. NH3, MsOH / 8 h / 55 °C
3: H2 / 5percent Pd/C / dimethylamine / 3 h / 3750.3 Torr / Ambient temperature
4: H2, MeSO3H / Pt/Al2O3 / 14 h / 11250.9 Torr
View Scheme
ethyl 2-(4-chlorobutyramido)acetate
125670-65-7

ethyl 2-(4-chlorobutyramido)acetate

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 83 percent / NH3 / methanol / 2 h / Ambient temperature
2: 45 percent / sodium ethoxide / ethanol / 8 h / 50 °C
View Scheme
2-(2-oxopyrrolidin-1-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide

2-(2-oxopyrrolidin-1-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Conditions
ConditionsYield
With trifluoroacetic acid for 3h; Inert atmosphere; Reflux;82 mg
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

2,6-dimethyl-4-pyrimidinyl p-toluenesulfonate
40227-86-9

2,6-dimethyl-4-pyrimidinyl p-toluenesulfonate

N-(2,6-dimethylpyrimidin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
1233503-26-8

N-(2,6-dimethylpyrimidin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide

Conditions
ConditionsYield
With 1,1'-bis-(diphenylphosphino)ferrocene; potassium carbonate; bis(dibenzylideneacetone)-palladium(0) In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;99%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

N,N-dimethylformamide diethyl diacetal
1188-33-6

N,N-dimethylformamide diethyl diacetal

N,N-Dimethyl-N'-(pyrrolidon-2-yl-1-acetyl)formamidine
92884-66-7

N,N-Dimethyl-N'-(pyrrolidon-2-yl-1-acetyl)formamidine

Conditions
ConditionsYield
In xylene at 100℃; for 7h;93%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

N,N-dimethylacetamide diethyl acetal
19429-85-7

N,N-dimethylacetamide diethyl acetal

N,N-Dimethyl-N'-(pyrrolidon-2-yl-1-acetyl)acetamidine
92884-67-8

N,N-Dimethyl-N'-(pyrrolidon-2-yl-1-acetyl)acetamidine

Conditions
ConditionsYield
In xylene for 6h; Heating;86%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

diethyl ether
60-29-7

diethyl ether

diphenylmethylpiperazine
841-77-0

diphenylmethylpiperazine

A

1-Benzhydryl-4-(2-oxo-1-(pyrrolidinyl)methylpiperazine

1-Benzhydryl-4-(2-oxo-1-(pyrrolidinyl)methylpiperazine

B

1-benzhydryl-4-(2-oxo-1(pyrrolidinyl)acetyl)methyl-piperazine

1-benzhydryl-4-(2-oxo-1(pyrrolidinyl)acetyl)methyl-piperazine

Conditions
ConditionsYield
In ethanolA n/a
B 85%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

2-Chloro-5H,6,7-dihydropyrrolo<1,2-a>imidazole
91417-91-3

2-Chloro-5H,6,7-dihydropyrrolo<1,2-a>imidazole

Conditions
ConditionsYield
With trichlorophosphate at 60℃; for 3h;84%
With trichlorophosphate at 85℃; for 15h; Sealed tube;65%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

docosahexaenoic acid
6217-54-5

docosahexaenoic acid

C28H40N2O3
1613318-03-8

C28H40N2O3

Conditions
ConditionsYield
Stage #1: docosahexaenoic acid With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃; for 0.5h;
Stage #2: 2-oxo-1-pyrrolidine acetamide In N,N-dimethyl-formamide for 2h;
75%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

3-phenylpyrazole
2458-26-6

3-phenylpyrazole

2-(2-oxo-5-(3-phenyl-1H-pyrazol-1-yl)pyrrolidin-1-yl)acetamide

2-(2-oxo-5-(3-phenyl-1H-pyrazol-1-yl)pyrrolidin-1-yl)acetamide

Conditions
ConditionsYield
With tetrabutylammonium tetrafluoroborate In acetonitrile at 20℃; for 4h; Electrochemical reaction; Inert atmosphere; Green chemistry;75%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole

2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole

Conditions
ConditionsYield
With phosphorus(V) oxybromide at 70℃; for 3h; Sealed tube;70%
With phosphorus(V) oxybromide at 85℃; for 0.5h;66%
With phosphorus(V) oxybromide at 85℃; for 0.5h;66%
With phosphorus(V) oxybromide at 70℃; for 3h;39.42%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

4-methyl-benzaldehyde
104-87-0

4-methyl-benzaldehyde

N-(4-methylbenzyl)-2-(2-oxopyrrolidin-1-yl)acetamide

N-(4-methylbenzyl)-2-(2-oxopyrrolidin-1-yl)acetamide

Conditions
ConditionsYield
With dirhodium tetraacetate; carbon monoxide In tetrahydrofuran at 140℃; for 22h; Autoclave; High pressure;62%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

myricetin
529-44-2

myricetin

C15H10O8*C6H10N2O2

C15H10O8*C6H10N2O2

Conditions
ConditionsYield
In isopropyl alcohol at 20℃; for 312h;54%
N-Methyl-2,2-diethoxypyrrolidine
826-41-5

N-Methyl-2,2-diethoxypyrrolidine

2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

N-(1-Methyl-2-pyrrolidinylidene)-α-(pyrrolid-2-on-1-yl)acetamidine
92884-68-9

N-(1-Methyl-2-pyrrolidinylidene)-α-(pyrrolid-2-on-1-yl)acetamidine

Conditions
ConditionsYield
In xylene for 6h; Heating;53%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

2-(chloromethyl)-3,5,6-trimethylpyrazine
123624-90-8

2-(chloromethyl)-3,5,6-trimethylpyrazine

2-(2-oxopyrrolidin-1-yl)-N-((3,5,6-trimethylpyrazin-2-yl)methyl)acetamide
1282538-38-8

2-(2-oxopyrrolidin-1-yl)-N-((3,5,6-trimethylpyrazin-2-yl)methyl)acetamide

Conditions
ConditionsYield
Stage #1: 2-oxo-1-pyrrolidine acetamide With sodium hydride In N,N-dimethyl-formamide at 25℃; for 1h; Inert atmosphere;
Stage #2: 2-(chloromethyl)-3,5,6-trimethylpyrazine In N,N-dimethyl-formamide at 60℃; for 5h; Inert atmosphere;
53%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

2-chloro-4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine
581098-43-3

2-chloro-4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine

N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-2-(2-oxopyrrolidin-1-yl)acetamide

N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-2-(2-oxopyrrolidin-1-yl)acetamide

Conditions
ConditionsYield
With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In N,N-dimethyl-formamide at 100℃; for 16h; Buchwald-Hartwig Coupling; Inert atmosphere;19%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

C6H11N2O4

C6H11N2O4

Conditions
ConditionsYield
for 13h; Irradiation;10%
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

nitrile of 2-oxopyrrolidine-1-acetic acid
57275-83-9

nitrile of 2-oxopyrrolidine-1-acetic acid

Conditions
ConditionsYield
With pyridine; N,N-dimethyl-formamide; trichlorophosphate 1.) acetonitrile, 50 deg C, 2.5 h, 2.) 0 deg C, 20 min; Yield given. Multistep reaction;
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

1-thiocarbamoylmethylpyrrolidine-2-thione
117947-07-6

1-thiocarbamoylmethylpyrrolidine-2-thione

Conditions
ConditionsYield
With diphosphorus pentasulfide; water 1.) xylene, reflux, 4 h, 2.) reflux, 30 min; Yield given. Multistep reaction;
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

Chloro(chloromethyl)dimethylsilane
1719-57-9

Chloro(chloromethyl)dimethylsilane

N,N-bis-(chloro-dimethyl-silanylmethyl)-2-(2-oxo-pyrrolidin-1-yl)-acetamide

N,N-bis-(chloro-dimethyl-silanylmethyl)-2-(2-oxo-pyrrolidin-1-yl)-acetamide

Conditions
ConditionsYield
With 1,1,1,3,3,3-hexamethyl-disilazane In acetonitrile Alkylation; Heating;
2-oxo-1-pyrrolidine acetamide
7491-74-9

2-oxo-1-pyrrolidine acetamide

2,5-dihydroxybenzoic acid.
490-79-9

2,5-dihydroxybenzoic acid.

2,5-dihydroxy-benzoic acid; compound with 2-(2-oxo-pyrrolidin-1-yl)-acetamide

2,5-dihydroxy-benzoic acid; compound with 2-(2-oxo-pyrrolidin-1-yl)-acetamide

Conditions
ConditionsYield
In acetonitrile at 70℃; for 0.0333333h;
In acetonitrile

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields